a commentary on the E5103 randomized phase III clinical study
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study / Roviello G.; Generali D.; Sobhani N.. - In: TRANSLATIONAL CANCER RESEARCH. - ISSN 2218-676X. - ELETTRONICO. - 8:(2019), pp. S94-S96. [10.21037/tcr.2018.10.17]
The combination of bevacizumab with chemotherapy is more beneficial in the metastatic setting rather than in the adjuvant setting for the treatment of HER2-negative breast cancer—a commentary on the E5103 randomized phase III clinical study
Roviello G.;
2019
Abstract
a commentary on the E5103 randomized phase III clinical study
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
